---
document_datetime: 2023-09-21 18:59:36
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/infanrix-hexa-h-c-296-p46-0991-epar-assessment-report_en.pdf
document_name: infanrix-hexa-h-c-296-p46-0991-epar-assessment-report_en.pdf
version: success
processing_time: 66.8793867
conversion_datetime: 2025-12-28 11:17:57.274369
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
27 June 2013 EMA/355023/2014

Committee for Medicinal Products for Human Use (CHMP)

## Assessment report under Article 46

## Infanrix hexa

International non-proprietary name: diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type b (hib) conjugate vaccine (adsorbed)

Procedure No. EMEA/H/C/000296/P46/099.1

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 1.ADMINISTRATIVEINFORMATION

## 1.1.ExecutiveSummary

A totalof9studiesevaluatingthecommercialformulationofInfanrixHexaareincludedinthecurrent primary immunization studies (116,106,100 and 109) or booster vaccination studies (120 and 117). Studies 120 and 117are thebooster studies of primary studies 116 and 109,respectively.Three studies, 110, 111 and 112, are antibody persistence studies.Reactogenicity and immunogenicity data of theprimaryandboosterstudiesarenotdifferentfrom thosereported ininitialstudies.Results of theantibodypersistencestudiesshowthatpersistingantibodieswerepresentin4to9yearold childrenvaccinatedduringinfancywith4dosesofInfanrixHexaandthesedataareinlinewithwhat wasreportedinpreviousstudies.

No SmPC and PL changes are proposed.

## 1.2.Recommendation

No further action required.

## 2. INTRODUCTION

On27/12/2012，theMAHsubmittedcompletedpaediatricstudiesforInfanrixHexa,inaccordancewith Article 46ofRegulation(EC)No1901/2006,as amended,onmedicinalproductsforpaediatricuse.

andthatthereisnoconsequentialregulatoryaction.

It is tobe noted that the synopses of these studieshad alreadybeensubmitted to theAgency,aspart ofarenewalproceduresubmittedinMarch20io,forwhichtheCommissionDecisionwasissuedon June 22nd 2010.

726/2004，thedatasubmitteddonotinfluencethebenefit-riskbalancefortheabovementioned for the above mentioned product, in line with the previous Assessment Report and Commission Decision.

GlaxoSmithKlineBiologicalshadreviewedtheresultsofthesestudiesandconcludedthatanupdateof the SmPC is not considered necessary.

<div style=\"page-break-after: always\"></div>

## 3.SCIENTIFICDISCUSSION

## Clinicalaspects

## 3.1.Introduction

TheMAHsubmittedfinalreportsfor:

- DTPa-HBV-IPV-1i6:AphaseII,observer-blind,randomizedstudytoevaluatethe formulationofDTPa-HBV-IPV/Hib,comparedtothecurrentlylicensedGSKBiologicals'DTPaHBV-IPV/Hib vaccine (Infanrix hexa) when administered to healthy infants at 2, 3 and 4 months of age.
- DTPa-HBV-IPV-120: A phase II open, study to assess the immunogenicity and reactogenicity of formulation of DTPa-HBV-IPV/Hib, or with GSK Biologicals' licensed DTPa-HBV-IPV/Hib vaccine (Infanrix hexa)in theprimaryvaccination study DTPa-HBV-IPV-116.
- DTPa-HBV-IPV-100:Anopen,multicentre,post-marketing surveillance(PMS)study toassess thesafetyandreactogenicityofGlaxoSmithKlineBiologicals'DTPa-IPV/Hibvaccine administered at3and 4 monthsof age and DTPa-HBV-IPV/Hibvaccine(Infanrixhexa) GSKBiologicals'DTPa-IPV/Hibvaccineat18monthsof ageinhealthyinfantswhoreceived hepatitisBvaccineatbirthand atonemonthofage.
- DTPa-HBV-IPV-106: A phase IIIb, open, randomised,multicentre study to evaluate the acellular pertussis-hepatitis B inactivated polio-conjugated Haemophilus influenzae type b vaccine（Infanrixhexa)inIndianinfantsaccordingtoa6-10-14weekschedule,when compared to Infanrix hexa given to Indian infants according to a 2-4-6 month schedule.
- DTPa-HBV-IPV-109:AphaseIII,partiallydouble-blindclinicaltrial toevaluatethe IPV/Hibvaccine(currentformulation)administeredinhealthyinfantsat3,4and5monthsof age. The immunogenicity, safety and reactogenicity of the DTPa-HBV-IPV vaccine was also evaluatedinathirdgroupofsubjects.
- DTPa-HBV-IPV-117:A phaseIV,partiallydouble-blind,multicentre studytoassess the immunogenicity and reactogenicity of GlaxoSmithKline(GSK) Biologicals'combined DTPa-HBVDTPa-HBV-IPV-109 (105910). The immunogenicity and reactogenicity of a booster dose of the DTPa-HBV-IPVvaccinewasevaluatedinathirdgroupofsubjectswhohadreceivedthis vaccineintheprimarystudy.

<div style=\"page-break-after: always\"></div>

- DTPa-HBV-IPV-110:Anopen,phase IV,multicentre studytoassess thelong-termpersistence healthychildren7to9yearsold,previouslyvaccinatedwith4dosesofGlaxoSmithKline(GSK) Biologicals'DTPa-HBV-IPV/Hibvaccineor4dosesofGSKBiologicals'HBVvaccine,inclinical trialsconductedbyGSKBiologicals.
- DTPa-HBV-IPV-111:An open,phaseIV,multicentre studyto assess the long-term persistence healthychildren4-6yearsold,previouslyvaccinatedwith4dosesof GlaxoSmithkline(GSK)
- DTPa-HBV-IPV-112: An open,phase IV, single-group multicentre study to assess the long-term persistenceofantibodiesagainsthepatitisBand theimmuneresponsetoahepatitisBvaccine challenge in children at 4-5years of age, previously primed and boosted in thefirst two years of lifewithGSKBiologicals'DTPa-HBV-IPV/Hibvaccine.

## 3.2.Clinicalstudies

## DTPa-HBV-IPV-116

- Primaryobjective:TodemonstratethattheimmunogenicityofanotherformulationofDTPaHBV-IPV/Hibvaccine(preservative-freeformulation)interms ofantibodyresponse to all vaccine antigensisnon-inferior tothatof theDTPa-HBV-IPV/Hibvaccine(licensed
- formulation of DTPa-HBV-IPV/Hib(preservative-free and preservative-containing formulation) toDTPa-HBV-IPV/Hibwerenotmet.
- Inthetwogroupsreceiving anotherformulationofDTPa-HBV-IPV/Hibvaccine,atleast92.6% and3andHibantigens.Seroprotectionratesof74%to80%wereobservedagainstpoliovirus type2inthe threegroups.Vaccineresponsewasseeninatleast89.6%ofthesubjects against pertussis antigens.
- all vaccine antigens, except for poliovirus type 2, after vaccination with the two another formulationsofDTPa-HBV-IPV/HibaScompared totheDTPa-HBV-IPV/Hibvaccine.
- The two another formulations of DTPa-HBV-IPV/Hibwere well tolerated,withsimilar incidences ofsolicitedsymptomsobservedafter theDTPa-HBV-IPV/Hibvaccine.Fever&gt;39.5°C(rectal
- None of the SAEs reported during the study was considered by the investigator to be causally relatedtovaccinationandalleventshadresolvedatthetimeoflastcontact.

Tables3and4presenttheassessmentoftheprimaryobjective.

<div style=\"page-break-after: always\"></div>

|                         |            | PF Group   | PF Group   | Control Group   | Control Group   | Difference in seroprotectionrate (Control Group minus PF Group)   | Difference in seroprotectionrate (Control Group minus PF Group)   | Difference in seroprotectionrate (Control Group minus PF Group)   |
|-------------------------|------------|------------|------------|-----------------|-----------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                         |            |            |            |                 |                 | Difference                                                        | 95%Cl                                                             | 95%Cl                                                             |
| Antibody                | Cut-off    | N          |            | N               |                 |                                                                   | LL                                                                | UL                                                                |
| Anti-diphtheria (Vero)  | 0.01610/m  | 138        | 97.8       | 145             | 100             | 2.17                                                              |                                                                   | 6.20*                                                             |
| Anti-diphtheria (ELISA) | 0.11Uml    | 138        | 98.6       | 146             | 100             | 1.45                                                              | -1.13                                                             | 5.13*                                                             |
| Anti-tetanus            | 0.11U/ml   | 138        | 100        | 146             | 100             | 0.00                                                              | -2.56                                                             | 2.71*                                                             |
| Anti-HBs                | 10ml0/ml   | 135        | 92.6       | 143             | 98.6            | 6.01                                                              | 1.42                                                              | 11.87                                                             |
| Anti-PRP                | 0.15 μg/ml | 138        | 95.7       | 145             | 95.2            | -0.48                                                             | -5.86                                                             | 4.94*                                                             |
| Anti-poliovirus type 1  | 8ED50      | 128        | 93.0       | 121             | 96.7            | 3.73                                                              | -2.06                                                             | 9.97*                                                             |
| Anti-poliovirus type2   | 8ED50      | 121        | 74.4       | 130             | 76.2            | 1.77                                                              | -8.89                                                             | 12.52                                                             |
| Anti-poliovirus type3   | 8ED50      | 131        | 96.2       | 128             | 97.7            | 1.47                                                              | -3.32                                                             | 6.59*                                                             |

| Antibody   | Group   |   N |   Adjusted GMC | Group   |   N |   Adjusted GMC | Ratio order             |   Value |   95%Cl | 95%Cl   |
|------------|---------|-----|----------------|---------|-----|----------------|-------------------------|---------|---------|---------|
| Anti-PT    | Control | 142 |           68.2 | PF      | 134 |           59.2 | Control Group /PF Group |    1.15 |    1.02 | 1.29*   |
| Anti-FHA   | Control | 140 |          199.3 | PF      | 133 |          136.9 | Control Group /PF Group |    1.46 |    1.26 | 1.67    |
| Anti-PRN   |         | 142 |          117.3 | PF      | 134 |           70.8 | Control Group/PF Group  |    1.66 |    1.4  | 1.95    |

<!-- image -->

One month after the third dose,

- ·The upper limits of the standardized asymptotic 95% CIs on the differences between the groups (Control Group minus PF Group)interms ofseroprotectionrates against diphtheria(ELISA and Vero), tetanus,poliovirus types1and3 andPRPwerebelow thepre-definedlimitof 10%.
- ·The upper limit of the 95% CI of the group ratio (Control Group divided by PF Group) of anti-PT GMCswasbelow thepre-defined limit of1.5.

Theupperlimitsofthestandardizedasymptotic95%CIsonthedifferencesbetweenthegroups (Control GroupminusPF Group)interms ofseroprotectionratesagainstHBsandpoliovirus type 2 wereabovethepre-definedlimitof10%andtheupperlimitsofthe95%CIsofthegroupratios of 1.5.

HencethePFformulationwasnotdemonstratedtobenon-inferiortothelicensedformulation. Similarly,thesecondaryobjectiveofnon-inferiorityofthePCformulationtothelicensedformulation poliovirusvirustype1exceededthepre-definedlimitof10%,andtheupperlimitof the95%CIfor theratioofanti-PT,FHAandPRNGMCsexceededthepre-definedlimitof1.5.

Thefeasibilityofthe formulationswasnotdemonstratedandtheywillnotbe further developed assuchby the Company.

<div style=\"page-break-after: always\"></div>

## DTPa-HBV-IPV-120

- Co-primaryobjectives:ToassesstheimmunogenicityofanotherformulationofDTPa-HBVIPV/Hib(preservative-freeorpreservative-containing),intermsofpersistenceofthe antibodiestoallvaccineantigensatthetimeoftheboostervaccination.
- ToassesstheimmunogenicityofaboosterdoseofDTPa-HBV-IPV/Hibvaccinegivenafter primary vaccinationwith another formulation of DTPa-HBV-IPV/Hib(preservative-free or preservative-containing), in terms of response to all vaccine antigens.
- Conclusions(Table 1):The antibody persistence at the pre-booster time pointwas in line withtheresultsoftheprimaryvaccinationstudy.
- One month after booster vaccination with the licensed formulation of Infanrix hexa, strong immune responses to all vaccine antigens were elicited in all three study groups and a marked increase in GMCs for antibodies against eachvaccine componentwas observed.
- The Infanrix hexa booster dose was well tolerated. Four SAEs were reported during the study, noneofwhichwereconsideredcausallyrelatedtovaccinationbytheinvestigator.Nofatal SAEswerereported in the course of the study.
- ThereactogenicityandsafetyofInfanrixhexainthisstudyareinagreementwiththe documentedsafetyprofileofthevaccine.

Table 1: The seroprotecton rates, peropositivity rates and GMCs ofantbodier to all vaceine antigems before and one month afer the booster vaccination (ATP cohost for immnmogenicity).

| Antibody         | Group   | Time   | N   | 鑫   | ds        | 1%6   | 1%6   | GMC*   | GMC*   | GMC*              |
|------------------|---------|--------|-----|-----|-----------|-------|-------|--------|--------|-------------------|
|                  |         | point  |     |     | S         | LL    | UL    | Value  | 95%CI  | 95%CI             |
|                  |         |        |     |     |           |       |       |        | LL     | UL                |
| Anti-diohtheria  | PF      | Pre    | 112 | 62  | 43        | 54.7  | 73.1  | 1000   | 0.058  | 0.071             |
| (201IUmlby ELISA |         | PIM    | 13  |     | 100       | 6.8   | 004   | 2.237  | 1.877  | 9997              |
| or≥0.016 1Umlby  | PC      | Pre    | 117 | 7   | 64.1      | 54.7  | 72.8  | 0.069  | 0.062  | 0.076             |
| Vero cell assay) |         |        | 119 | 118 | 09.2      | 95.4  | 100   | 2.242  | 1.868  | 2.889             |
|                  |         | Pre    | 111 | 67  | 75.0      | 68.5  | 82.7  | 0.084  | 0.073  | 0.097             |
|                  |         |        |     |     | 119119100 | 99    |       |        |        | 1003.95233654.642 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Antibody                | Group   | Time point   | N       |         | SPIS+    | 95%CI     | 95%CI    | GMCIT      | GMCIT      | GMCIT      |
|-------------------------|---------|--------------|---------|---------|----------|-----------|----------|------------|------------|------------|
| Antibody                | Group   | Time point   | N       |         | SPIS+    | L         | UL       | Value      | 10%6       | 10%6       |
| Antibody                | Group   | Time point   | N       |         | SPIS+    | L         | UL       | Value      |            | UL         |
| Anti-tetanus (20.1U/m0) | PF      | Po           | 112     | 93      | 83.0     | 74.8      | 89.5     | 0.216      | 0.184      | 0.254      |
| Anti-tetanus (20.1U/m0) |         | PIM)         | 113     | 113     | 100      | 96.8      | 0        | 9.799      | 8.390      |            |
| Anti-tetanus (20.1U/m0) | PC      | Pe           | 117     | 103     | 88.0     | 80.7      | 93.3     | 0.248      | 0.213      | 0.289      |
| Anti-tetanus (20.1U/m0) |         | PIM)         | 119     | 118     | 99.2     | 95.4      | 100      | 9.136      | 7.838      | 10.648     |
| Anti-tetanus (20.1U/m0) | 00Q     | P            | 111     | S6      | 85.6     | 77.6      | 91.5     | 0.261      | 0219       |            |
|                         |         | PM           | 119     | 119     | 100      | 96.9      | 100      | 10.833     | 9.505      | 12347      |
|                         | PF      | PMI          | 109     | 80 111  | 734 100  | 64.1 96.7 | 81.4 100 | 78 150.9   | 7 132.9    | 9.1 171.2  |
|                         | PC      |              | 111     |         |          | 63.1      |          |            |            |            |
|                         |         | Fre          | 112     | 81      | 723      |           | 80.4     | 7.0        | 1          | 8.1        |
|                         |         | PIM)         | 119     | 118     | 99.2     | 95.4      | 100      | 117.1      | 101.5      | 135.0      |
|                         |         | Pe           | 110     | 93      | 84.5     | 76.4      | 90.7     | 89         | 1.7        | 03         |
|                         |         | W1d          | 119     | 119     | 100      | 96.9      | 100      | 153.7      | 135.1      | 174.9      |
|                         | PF      | Pe           | 110     | 106     | 96.4     | 91.0      | 99.0     | 217        | 18.1       | 25.9       |
|                         |         | PIM)         | 112     | 112     | 100      | 96.8      | 100      | 609.8      | 534.1      | 695.7      |
|                         | PC      | Pe           | 112     | 107     | 95.5     | 89.9      | 98.5     | 22.1       | 18.5       | 26.2       |
|                         |         |              | 119     | 118     | 99.2     | 05.4      | 100      | 533.7 33.7 | 4830       | 615.1      |
|                         |         | PIM)         | 109     | 109 119 | 100 100  | 96.7 96.9 | 100 100  | 7919       | 27.6 708.8 | 41.1 884.8 |
| Anti-PRN (25EL.Um)      | PF      | PIM Pre      | 119 112 | 81      | 72.3     | 63.1      | 80.4     | 86         | 1.1        | 10.3       |
| Anti-PRN (25EL.Um)      |         | PIM)         | 113     | 113     | 100      | 96.8      | 100      | 308.5      | 261.3      | 364.2      |
| Anti-PRN (25EL.Um)      | Od      |              | 117     |         | 735      | 64.5      | 81.2     | 87         | 7.3        | 102        |
| Anti-PRN (25EL.Um)      |         | PIM          | 118     | 117     | 99.2     | 95.4      | 10       | 311.7      | 260.3      | 373.2      |
| Anti-PRN (25EL.Um)      | po      | Pe           | 111     | 99      | 89.2     | 81.9      | 94.3     | 15.3       | 126        | 18.5       |
|                         |         | PIM          | 119     | 119     | 100      | 96.9      | 100      | 564.1      | 489.5      | 650.1      |
|                         | PF      | Pe           | 111     | 106     | 95.5     | 89.8      | 98.5     | 84.3       | 65.7       | 108.2      |
| Anti-HBs (10mlU/ml      | PC      | PIM)         | 111 117 | 110 112 | 09.1 057 | 95.1 903  | 100 98.6 | 3291.7     | 2373.6     | 4565.0     |
| Anti-HBs (10mlU/ml      |         | Pre          |         |         |          |           |          | 86.2       | 67.8       | 109.6      |
| Anti-HBs (10mlU/ml      |         | PM           | 118     | 117     | 99.2     | 95.4      | 100      | 3528.1     | 2548.1     | 4868.9     |
|                         | Contrdl | Pre          | 110     | 106     | 96.4     | 91.0      | 99.0     | 139.8      | 107.2      | 182.3      |
|                         |         | PM           | 18      | 118     | 100      | 06.9      | 100      | 6132.7     | 45878      | 8197.9     |
|                         | PF      |              |         |         | 60.9     | 51.1      | 70.1     | 12.9       |            |            |
|                         | PC      | P特           | 110     | 67      | 99.1     | 95.1      | 100      |            | 10.3       | 16.3       |
|                         |         | PIMI P       | 111 117 | 10 76   | 65.0     | 55.6      | 73.5     | 726.3 15.2 | 560.4 123  | 9414 18.9  |
|                         |         | PM)          | 117     | 117     | 100      | 96.9      | 100      | 9424       | 734.1      | 27.4       |
|                         | p000    | P            | 109     | 84      | 77.1     | 680       | 84.6     | 21.6       | 17.1       | 1209.7     |
|                         |         | PIM}         | 113     | 112     | 09.1     | 790       | 100      | 1288.8     | 1028.1     | 1614.0     |

<div style=\"page-break-after: always\"></div>

| Antibody                          | Group   | Time   | N   |     | SPIS+   | 1%6   | 1%6   | GMCT   | GMCT   | GMCT   |
|-----------------------------------|---------|--------|-----|-----|---------|-------|-------|--------|--------|--------|
|                                   |         | poinf  |     |     |         | LL    | U     | Value  | 95%Cl  | 95%Cl  |
|                                   |         |        |     |     |         |       |       |        | LL     | UL     |
| Anti-polio virus type2 (28ED50)   | PF      | Pre    | 111 |     | 43.2    | 33.9  | 53.0  | 0.1    | 73     | 113    |
| Anti-polio virus type2 (28ED50)   |         | PM     | 112 | 110 | 98.2    | 93.7  | 866   | 712.8  | 529.1  | 960.4  |
| Anti-polio virus type2 (28ED50)   | PC      | Pre    | 117 | 51  | 43.6    | 34.4  | 53.1  | 8.7    | 7.2    | 10.5   |
| Anti-polio virus type2 (28ED50)   |         | P(M)   | 117 | 117 | 100     |       | 100   | 812.9  | 632.8  | 1044.3 |
| Anti-polio virus type2 (28ED50)   | Control | Pre    | 109 | 56  | 51.4    | 41.8  | 61.1  | 11.8   | 9.2    | 15.0   |
| Anti-polio virus type2 (28ED50)   |         | PM     | 113 | 112 | 99.1    | 95.2  | 100   | 12310  | 961.0  | 1576.9 |
| Anti-polio virus type3 (28 ED 50) | PF      | Pre    | 11第 | 58  | 52.3    | 42.6  | 618   | 9.5    | 7.9    | 11.6   |
| Anti-polio virus type3 (28 ED 50) |         | M      | 112 |     | 99.1    | 95.1  | 100   | 760.0  | 591.0  | 1029.3 |
| Anti-polio virus type3 (28 ED 50) | PC      | Pre    | 117 | 77  | 65.8    | 58.5  | 74.3  | 18.0   | 128    | 20.4   |
| Anti-polio virus type3 (28 ED 50) |         | PM     | 117 | 117 | 100     |       | 100   | 1145.8 | 8916   | 1472.5 |
| Anti-polio virus type3 (28 ED 50) | Control | Pre    | 109 | 82  | 75.2    | 66.0  | 83.0  | 21.3   | 16.4   | 27.7   |
| Anti-polio virus type3 (28 ED 50) |         | P(M    | 113 | 美   | 100     | 93.8  | 100   | 1794.8 | 1426.6 | 2257.7 |
| Anti-PRP (20.15μg/ml)             | PF      | Pre    | 111 | 71  | 64.0    | 54.3  | 72.9  | 0.249  | 0.199  | 0.310  |
| Anti-PRP (20.15μg/ml)             |         | PM     | 112 | 12  | 100     | 96.8  | 100   | 36.866 | 28.610 | 47.504 |
| Anti-PRP (20.15μg/ml)             | Od      | Pre    | 117 | 87  | 74.4    | 65.5  | 82.0  | 0314   | 0252   | 0.392  |
| Anti-PRP (20.15μg/ml)             |         | P(M)   | 119 | 119 | 100     | 96.9  | 100   | 35.318 | 27.447 | 45.445 |
| Anti-PRP (20.15μg/ml)             |         | Pre    | 11季 | 92  | 82.9    |       | 89.4  | 0.487  | 0.383  | 0.620  |
| Anti-PRP (20.15μg/ml)             |         | P1M)   | 119 | 119 | 100     | 96.9  | 100   | 77.087 | 60.224 | 98.672 |

formulation

PFSubjects who received the age and thelicensed formulation of DTPa-HBV-PVHb booster doseat 16-20monthe of age

at23ang4monthsof at23a4

monhs of ageand the lioensed formulation oiDTPa-HBv-IPvHio boosterdoseat 16-20monhsof age

PC=Subjects who received be ormulaticn

Contol = Subjects who received the licensed formulation of DTPa-HBV-PVmib at 2,and 4 montas oi age and as oosterdocat 16-20monthsofage

=GMCvalues for ant-dphthena based on EUSA

N=numberofsubjects wibiavalableresults

SP=Seroprotecton;S+=Seroposiivity n[%）= number (percentege)oisubjects with antibooy concentratons/liresabove the specifiedcut-off

95%CI=95%conicenceintervalLL=Lower Limit,UL=Upoer Limit

PRE=blood cample taken betore thekoosterdose

Pl (M1)=blood cemole one month afer e booster dose

<div style=\"page-break-after: always\"></div>

## DTPa-HBV-IPV-100

- Primaryobjective:ToassessthesafetyandreactogenicityoftheDTPa-HBV-IPV/Hibvaccine andDTPa-IPV/Hibvaccine.
- Conclusions(Table1):Boththestudyvaccineswerewelltoleratedanddemonstratedagood safetyprofile.
- TwoSAEs(febrileconvulsionsandexanthemasubitum)werereportedbyonesubjectafter administrationoftheboosterdosethatwereconsideredbytheinvestigatortohavecausal relationshiptothestudyvaccine.Botheventswereresolvedduringthecourseofthestudy.

| Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   | Synopiis table 1: Incidence of symptoms (per subject) reponted duing the 4-day Day 0-3) follow-up peniodaRtervaccination(TotalVaecunatedcohort)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Symptom                                                                                                                                           | Type                                                                                                                                              | Primary vaccination (N=702)                                                                                                                       | Primary vaccination (N=702)                                                                                                                       | Primary vaccination (N=702)                                                                                                                       | Primary vaccination (N=702)                                                                                                                       | Booster vaccination (N=688)                                                                                                                       | Booster vaccination (N=688)                                                                                                                       | Booster vaccination (N=688)                                                                                                                       |
|                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   | LL                                                                                                                                                | UL                                                                                                                                                | n                                                                                                                                                 | LL                                                                                                                                                | UL                                                                                                                                                |
| OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      | OverallIncidenceofnature ofsymotoms(solicitedandunsolicited)                                                                                      |
| Any                                                                                                                                               | Any                                                                                                                                               | 559                                                                                                                                               | 79.6                                                                                                                                              | 76.5                                                                                                                                              | 82.6                                                                                                                                              | 335                                                                                                                                               | 48.7                                                                                                                                              | 52.5                                                                                                                                              |
| symptom                                                                                                                                           | Grade3&4                                                                                                                                          | 41                                                                                                                                                | 58                                                                                                                                                | 42                                                                                                                                                | 7.8                                                                                                                                               | 13                                                                                                                                                | 44.9 1.9 1.0                                                                                                                                      | 3.2                                                                                                                                               |
| Genenal                                                                                                                                           | 疯的                                                                                                                                                | 521                                                                                                                                               | 74.2                                                                                                                                              | 70.8                                                                                                                                              | 77.4                                                                                                                                              | 285 41.                                                                                                                                           | 37.7                                                                                                                                              | 452                                                                                                                                               |
| symotoms                                                                                                                                          | Gra384                                                                                                                                            | 29                                                                                                                                                | 4业                                                                                                                                                | 2.8                                                                                                                                               | 5.9                                                                                                                                               |                                                                                                                                                   | 13 0.8                                                                                                                                            | 25                                                                                                                                                |
|                                                                                                                                                   | Any                                                                                                                                               | 315                                                                                                                                               | 44.9                                                                                                                                              | 41.1                                                                                                                                              | 48.6                                                                                                                                              | 213                                                                                                                                               | 31.0 27.5                                                                                                                                         | 34.8                                                                                                                                              |
| symptoms                                                                                                                                          | Grade384                                                                                                                                          | 15                                                                                                                                                | 2.1                                                                                                                                               | 1.2                                                                                                                                               | 3.5                                                                                                                                               | 5                                                                                                                                                 | 0.2                                                                                                                                               | 1.7                                                                                                                                               |
| 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   | 07 N=697 N°=565                                                                                                                                   |
| Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           | Solicited localsymptoms                                                                                                                           |
| Pain                                                                                                                                              | Any                                                                                                                                               | 227                                                                                                                                               | 32.6                                                                                                                                              | 29.1                                                                                                                                              | 36.2                                                                                                                                              | 166                                                                                                                                               | 29.4 25.7                                                                                                                                         | 33.3                                                                                                                                              |
|                                                                                                                                                   | Grade3                                                                                                                                            |                                                                                                                                                   | 1                                                                                                                                                 | 0.5                                                                                                                                               | 22                                                                                                                                                | 05                                                                                                                                                | 0.1                                                                                                                                               | 1.5                                                                                                                                               |
| Redness                                                                                                                                           | Kuy                                                                                                                                               | 222                                                                                                                                               | 31.9                                                                                                                                              | 28.4                                                                                                                                              | 35.5                                                                                                                                              | 148 26.2                                                                                                                                          | 22.6                                                                                                                                              | 30.0                                                                                                                                              |
| (mm)                                                                                                                                              | >20mm                                                                                                                                             | 2                                                                                                                                                 | 0.3                                                                                                                                               | 0.0                                                                                                                                               | 10                                                                                                                                                | 2                                                                                                                                                 | 04 0.0                                                                                                                                            | 13                                                                                                                                                |
| Swelling                                                                                                                                          | Any                                                                                                                                               | 172                                                                                                                                               | 24.7                                                                                                                                              | 21.5                                                                                                                                              | 28.1                                                                                                                                              | 115 20.4                                                                                                                                          | 17.1                                                                                                                                              | 23.9                                                                                                                                              |
| (mm)                                                                                                                                              | 220mm                                                                                                                                             | 6                                                                                                                                                 | 0.9                                                                                                                                               | 0.3                                                                                                                                               |                                                                                                                                                   | 1                                                                                                                                                 | 0.0                                                                                                                                               | 1.0                                                                                                                                               |
| 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     | 02 Solicited general symptoms                                                                                                                     |
| Drowsiness                                                                                                                                        | A                                                                                                                                                 | 261                                                                                                                                               | 37.4                                                                                                                                              | 33.8                                                                                                                                              | 41.2                                                                                                                                              | 89                                                                                                                                                | 15.8 12.8                                                                                                                                         | 19.0                                                                                                                                              |
|                                                                                                                                                   | Grade3                                                                                                                                            | 6                                                                                                                                                 | 0.9                                                                                                                                               | 3                                                                                                                                                 | 19                                                                                                                                                |                                                                                                                                                   | 0.2 0.0                                                                                                                                           | 1.0                                                                                                                                               |
|                                                                                                                                                   | Related                                                                                                                                           | 210                                                                                                                                               | 30.1                                                                                                                                              | 26.7                                                                                                                                              | 33.7                                                                                                                                              | 89                                                                                                                                                | 15.8 12.8                                                                                                                                         | 19.0                                                                                                                                              |
|                                                                                                                                                   | Grade3* Rel                                                                                                                                       | 4                                                                                                                                                 | 0.6                                                                                                                                               | 02                                                                                                                                                | 1.5                                                                                                                                               |                                                                                                                                                   | 02 0.0                                                                                                                                            | 1.0                                                                                                                                               |
| Fever                                                                                                                                             | Any (237.5°0)                                                                                                                                     | 252                                                                                                                                               | 36.2                                                                                                                                              | 32.6                                                                                                                                              | 39.8                                                                                                                                              | 152 26.9                                                                                                                                          | 23.3                                                                                                                                              | 30.8                                                                                                                                              |
| Axillaryin                                                                                                                                        | 0.086                                                                                                                                             | 84                                                                                                                                                | 9.2                                                                                                                                               | 7.1                                                                                                                                               |                                                                                                                                                   | 7.3                                                                                                                                               | 5.3                                                                                                                                               | 97                                                                                                                                                |
|                                                                                                                                                   | 0.986                                                                                                                                             | 24                                                                                                                                                | 3.4                                                                                                                                               | 22                                                                                                                                                | 5.1                                                                                                                                               | 13                                                                                                                                                | 23 12                                                                                                                                             |                                                                                                                                                   |
|                                                                                                                                                   | >39.00                                                                                                                                            | 10                                                                                                                                                |                                                                                                                                                   | 07                                                                                                                                                | 26                                                                                                                                                | 1.1                                                                                                                                               | 0.4                                                                                                                                               | 23                                                                                                                                                |
|                                                                                                                                                   | >39.5°0                                                                                                                                           |                                                                                                                                                   | 0.7                                                                                                                                               | 0.2                                                                                                                                               | 17                                                                                                                                                | 2 04                                                                                                                                              | 0.0                                                                                                                                               | 1.3                                                                                                                                               |
|                                                                                                                                                   | 40.0°0                                                                                                                                            | 0                                                                                                                                                 | 0.0                                                                                                                                               |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   | 02 0.0                                                                                                                                            | 1.0                                                                                                                                               |
|                                                                                                                                                   | Related                                                                                                                                           | 238                                                                                                                                               | 31                                                                                                                                                | 30.6                                                                                                                                              | 37.8                                                                                                                                              | 149                                                                                                                                               | 22.8                                                                                                                                              | 30.2                                                                                                                                              |
|                                                                                                                                                   | >39.0°0*Rel                                                                                                                                       | 9                                                                                                                                                 | 1.3                                                                                                                                               | 0.6                                                                                                                                               | 24                                                                                                                                                | 26.4 1.1                                                                                                                                          | 0.4                                                                                                                                               | 23                                                                                                                                                |
| Initabiity                                                                                                                                        | A腺                                                                                                                                                | 341                                                                                                                                               | 48.9                                                                                                                                              | 45.2                                                                                                                                              | 52.7                                                                                                                                              | 163                                                                                                                                               | 28.8 25.1                                                                                                                                         | 32.8                                                                                                                                              |
|                                                                                                                                                   | Grade3                                                                                                                                            | 17                                                                                                                                                | 2.4                                                                                                                                               | 1.4                                                                                                                                               | 39                                                                                                                                                | 2                                                                                                                                                 | 0.4 0.0                                                                                                                                           |                                                                                                                                                   |
|                                                                                                                                                   | Grade4                                                                                                                                            | 2                                                                                                                                                 | 03                                                                                                                                                | 00                                                                                                                                                | 1.0                                                                                                                                               | 0 00                                                                                                                                              | 00                                                                                                                                                | 0.7                                                                                                                                               |
|                                                                                                                                                   | Related                                                                                                                                           | 266                                                                                                                                               | 38.5                                                                                                                                              | 34.8                                                                                                                                              | 42.2                                                                                                                                              | 162                                                                                                                                               | 28.7 25.0                                                                                                                                         | 32.6                                                                                                                                              |
|                                                                                                                                                   | Grade3Grade 4*Rel                                                                                                                                 | 12                                                                                                                                                |                                                                                                                                                   | 0.9                                                                                                                                               | 3.0                                                                                                                                               | 0.4                                                                                                                                               | 00                                                                                                                                                |                                                                                                                                                   |
|                                                                                                                                                   |                                                                                                                                                   | 276                                                                                                                                               | 39.6                                                                                                                                              | 35.9                                                                                                                                              | 43.3                                                                                                                                              | 118                                                                                                                                               | 20.9                                                                                                                                              |                                                                                                                                                   |
| Lossof                                                                                                                                            | A                                                                                                                                                 |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   |                                                                                                                                                   | 176 02                                                                                                                                            | 24.5 10                                                                                                                                           |
| appetite                                                                                                                                          | Grade3 Related                                                                                                                                    | 1                                                                                                                                                 | 0.1 30.3                                                                                                                                          | 0.0 26.9                                                                                                                                          | 0.8                                                                                                                                               |                                                                                                                                                   | 0.0 20.7 17.4                                                                                                                                     | 24.3                                                                                                                                              |
|                                                                                                                                                   | Grude3+Rel                                                                                                                                        | 211                                                                                                                                               | 0.0                                                                                                                                               | 00                                                                                                                                                | 33.8 0.5                                                                                                                                          | 117 02                                                                                                                                            | 00                                                                                                                                                | 10                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## DTPa-HBV-IPV-106

- Primaryobjective:Toassesstheantibodyresponsetopertussistoxoid(PT),filamentous haemagglutinin (FHA), pertactin (PRN) and poliovirus types 1, 2, 3 after a three-dose primary vaccinationcoursewithInfanrixhexa.
- Conclusions(Table1):Theimmunogenicityobjectiveswerenotassessedinthisstudydue toabacterialcontaminationofthesamplespriortoshipmentforanalysis.TheInfanrixhexa vaccinewassafeandwelltoleratedwhenadministeredtoIndianinfantsaccordingtoeithera 6-10-14week0ra2-4-6monthschedule.
- SAEswerereportedforthreesubjectseachinthe6-10-14weekgroupand the2-4-6month group in this study. None of these was considered by the investigator to have causal relationshiptovaccination.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## DTPa-HBV-IPV-109

- Primaryobjective:TodemonstratethattheimmunogenicityoftheDTPa-HBV-IPV/Hib vaccine(newformulation)intermsofresponsetoallvaccineantigensisnon-inferiortothatof the DTPa-HBV-IPV/Hib vaccine (current formulation), one month after a three-dose primary vaccination course.
- Criteriafornon-inferiority(onemonthafterthethirdvaccinedose):
- Forhepatitis B,PRP,diphtheria,tetanus and poliovirus types 1,2and 3,theupper limitofthestandardizedasymptotic95%CIonthegroupdifference[DTPa-HBVIPV/Hib(currentformulation)minus DTPa-HBV-IPV/Hib(newformulation)]for the percentage of seroprotected subjectsisbelow10%.
- theupperlimitof the95%CIontheGMCratio[DTPa-HBV-IPV/Hib(current formulation)divided byDTPa-HBV-IPV/Hib(newformulation)]isbelow 1.5.
- Conclusions(Table1):Theprimaryobjectivewasmet.Thepreservative-freeformulationof theDTPa-HBV-IPV/Hibvaccinewasshowntobenon-inferiortothecurrentformulationof the vaccine interms of seroprotection against diphtheria,tetanus,hepatitis,poliovirus types 1,2&amp; 3 and Haemophilus influenzae type b and in terms of antibody GMCs against PT, FHA and PRN.
- Seroprotectionrates against diphtheria,tetanus,HBs,poliovirus types 1,2and 3and seropositivityrates againstPT,FHA andPRNwere≥96.2%inthe threegroupsand seroprotectionratesagainstPRPwere≥94.2%withthetwoDTPa-HBV-IPV/Hibvaccine formulations.
- Thethreevaccineswerewelltoleratedandthepreservative-freeformulationdidnotmodify thereactogenicityoftheDTPa-HBV-IPV/Hibvaccine.Asignificantlylowerincidenceofsome generalsymptoms(drowsinessandfever)wasobservedaftervaccinatingwithDTPa-HBV-IPV (preservative-free)as compared toDTPa-HBV-IPV/Hib(preservative-free).

| Antbody              | HexaNEW Group               | HexaNEW Group               | HaxaREF Group               | HaxaREF Group               | Diffarencsinseroprotection rate(HexaREF Grop minu HexaNEW Group)   | Diffarencsinseroprotection rate(HexaREF Grop minu HexaNEW Group)   | Diffarencsinseroprotection rate(HexaREF Grop minu HexaNEW Group)   |
|----------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                      | N                           | SP%                         | N                           | SP%                         |                                                                    | 10%58                                                              | 10%58                                                              |
|                      |                             |                             |                             |                             |                                                                    | LL                                                                 | UL                                                                 |
| Ars-dohtaro[2 0.1Um  | 04                          | 7.1                         | 106                         | 9.2                         | 89                                                                 | -6.80                                                              | 4.84*                                                              |
| Art-tetms (0.1Ul)    | 04                          | 065                         | 108                         | 100                         | 0.96                                                               | .255                                                               | 5.25*                                                              |
| ArHes0mm             |                             | 9.1                         | 123                         | 98.4                        | 076                                                                | 4.97                                                               | 3.24                                                               |
| Art-pclows128E050)   |                             | 100.0                       |                             | 100                         | 0.00                                                               | -5.50                                                              | 6.02                                                               |
| Arl-polose2(28E050)  |                             | 100.0                       | 74                          | 100                         | 0.00                                                               | 4.93                                                               | 5.66*                                                              |
| Artpoowusoe3128E050) | 71                          | 100.0                       | 72                          | 100                         | 0.00                                                               | -5.07                                                              | 5.13                                                               |
| At-PRP(0.15ugml      | 104                         | 4.2                         | 106                         | 95.0                        | 2.00                                                               | 4.31                                                               | 8.74*                                                              |
|                      | HexaNEW Group HexaREF Group | HexaNEW Group HexaREF Group | HexaNEW Group HexaREF Group | HexaNEW Group HexaREF Group | HexaNEW Group HexaREF Group                                        | HexaNEW Group HexaREF Group                                        | HexaNEW Group HexaREF Group                                        |
|                      | N                           | GMC                         | N                           | GMC                         | GMO nio (HxaREF Group * HexaNEW Group                              | GMO nio (HxaREF Group * HexaNEW Group                              | GMO nio (HxaREF Group * HexaNEW Group                              |
|                      |                             |                             |                             |                             |                                                                    | 95%C*                                                              | 95%C*                                                              |
|                      |                             |                             |                             |                             |                                                                    | LL                                                                 | UL                                                                 |
| Ar-PT                | 28                          | 75.2                        | 124                         | 712                         | 1.06                                                               | 0.90                                                               | 1.24*                                                              |
| Ar-FHA               |                             | 215.8                       | 125                         | 1780                        | 1.21                                                               | 1.02                                                               | 1.44*                                                              |
| At-PRN               | 127                         | 1467                        |                             |                             | 1.06                                                               | 0.86                                                               |                                                                    |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## DTPa-HBV-IPV-117

- Primaryobjective:TodemonstratethattheimmunogenicityoftheDTPa-HBV-IPV/Hib the DTPa-HBV-IPV/Hibvaccine(currentformulation),onemonthafter thebooster dose.
- Criteriafornon-inferiority(onemonthaftertheboosterdose):
- For hepatitis B, polyribosyl-ribitol-phosphate, diphtheria, tetanus and poliovirus types 1, 2 and 3，theupperlimitofthestandardizedasymptotic95%confidenceinterval(CI)onthegroup difference [DTPa-HBV-IPV/Hib (current formulation) minus DTPa-HBV-IPV/Hib (new formulation)]for thepercentage of seroprotected subjects is≤10%.
- antipertactinantibodyconcentrations,theupperlimitof the95%CIonthegeometricmean IPV/Hib(new formulation)]is≤ 1.5.
- Conclusions (see Table below): The immunogenicity results of this study must be was lower thanexpected.
- Theboosterdoseofthepreservative-freeformulationoftheDTPa-HBV-IPV/Hibvaccinewas non-inferior to thepreservative-containingformulationof thevaccine in terms of immunogenicityagainstallantigenswiththeexceptionofPT.Hence,theprimaryobjectivewas thereforelimitstheabilitytoconcludeontheprimaryobjective.
- levels of antibodies were observed against all antigens in all the groups.
- Boostervaccinationwiththepreservative-freeformulationoftheDTPa-HBV-IPV/Hibvaccine receivingpreservative-containingformulationoftheDTPa-HBV-IPV/Hibvaccineand theDTPaHBV-IPVvaccine.
- The threevaccineswerewelltolerated;noSAErelated tostudyvaccinationwasreported.
- vaccineinthisstudyisinagreementwiththedocumentedsafetyprofileofthepreservativecontainingInfanrixhexavaccine.

<div style=\"page-break-after: always\"></div>

Imunogenicity recults:The iamunogenicty analysiswas perfoned on theATP cohont(piany analyis)and on the Total Vaccimated cohort. Table 1, 2 3 and 4 prezent the renule for ATP analyvit. Non-nferiorio anaiysicOne month afer the booster doze

- The upper limit of the standadized asymptotie 95% CI on the difference berween gzoups (HexaREF Group mnus HexaNEW Group)n termr of diphthenia, tetanus, hepaias B,PRF and poliovrus bpez1,2and3seroprotectionrates were all below 10%
- The upper limit of the 95% CI on the GMC ratio (HexaREF Group GMC divided by HexaNEW Group GMC) wa balow 1.5 foranh-FHAsndantiPRN GMOand not for anti-PT GMCs

Thus,non-inferionty of tha new formulationoftheDTPa-HBV-IPV/Hib vaocine to hecurant formulation ofthe waccine was not demonceated im terms of immse response to all vaccine antizen. The failue to meet the pre-defined clzicallimit of noninfariority for anti-PT GMC ratio could be atibued to the reduced sample size and power.

| Antibody                        | HexaNEW Group   | HexaNEW Group   | HexaREF Group   | HexaREF Group   | Difference in seroprotection rate (HexaREF Group minus HexaNEW Group)   | Difference in seroprotection rate (HexaREF Group minus HexaNEW Group)   | Difference in seroprotection rate (HexaREF Group minus HexaNEW Group)   |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                                 | N               | SP%             | N               | SP%             | %                                                                       | 15%9                                                                    | 15%9                                                                    |
|                                 | N               | SP%             | N               | SP%             | %                                                                       | LL                                                                      | UL                                                                      |
| Anti-diohtheria(20.1IU/ml)      | 77              | 98.7            |                 | 98.2            | -2.50                                                                   | -9.48                                                                   | 3.62                                                                    |
| Anti-tetanus(2 0.11U/m)         |                 | 98.7            | 79              | 98.7            | 0.03                                                                    | 5.68                                                                    | 5.88                                                                    |
| Anti-HBs(10 mIUm)               |                 | 96.7            | 92              | 100             | 3.30                                                                    | 0.60                                                                    | 9.27                                                                    |
| Anti-poliovirus type 1( 8 ED50) | 55              | 100             |                 | 100             | 0.00                                                                    | 7.07                                                                    | 6.59                                                                    |
| Anti-poliovirus type2 (28ED50)  | 55              | 100             |                 | 100             | 0.00                                                                    | 707                                                                     | 6.59                                                                    |
| Anti-poliovirus type3(28ED50)   | 55              | 100             | 52              | 100             | 0.00                                                                    | 6.94                                                                    | 6.59                                                                    |
| Anti-PRP 0.15 μomD              | 76              | 97.弄            | 79              | 98.7            | 137                                                                     | 449                                                                     | 8.01                                                                    |
| Antibody                        | HexaREF Group   | HexaREF Group   | HexaNEW Group   | HexaNEW Group   | GMCratio HexaREF Group/ HexaNEwGroup                                    | GMCratio HexaREF Group/ HexaNEwGroup                                    | GMCratio HexaREF Group/ HexaNEwGroup                                    |
|                                 | N               | GMC             | N               |                 | GMC ratio                                                               | 95%                                                                     | 95%                                                                     |
|                                 | N               | GMC             | N               |                 | GMC ratio                                                               | L                                                                       | U                                                                       |
| Anti-PT                         | 70              | 84.2            | 84              | 65.5            | 1.29                                                                    | 0.85                                                                    | 1.94                                                                    |
| Anti-FHA                        |                 | 428.3           |                 | 476.6           | 0.00                                                                    | 0.60                                                                    | 1.34                                                                    |
| Anti-PRN                        | 77              | 384.1           | 89              | 418.季           | 0.92                                                                    | 0.57                                                                    | 1.47                                                                    |

Table l: Difference between the HexaREF Group and the HexaNEW Group m terms of seroprotechon rates and GMC ratos, one month after the thud dose for the ATP cohort for immunogenicity.

pe01Aps euAunuMe0 eupa=N current stady（110478}

pps]A0ps=

cuentsay110478]

N= nwer ot suojecis wtr avalake esufs

95Cl=5Stardidasympoicconenceinterval5oonenceeva foGMCo

GvC*geometiemeonanthonyconcertation

LL =fowemit UL =wogr l

## DTPa-HBV-IPV-110

- vaccineinsubjectsaged7to9years,previouslyprimedandboostedwith4dosesofInfanrix hexainthefirsttwoyearsoflife.
- Conclusions(seeTablebelow):InDTPa-HBV-IPV/Hibvaccineesat8yearsofage,on average6.5yearsaftertheDTPa-HBVIPV/Hibboosterdosegiveninthesecondyearoflife, mIU/ml.
- Atthattime,over90%of theDTPa-HBV-IPV/Hibvaccinees(intheATPpersistencecohort)had seroprotectiveantibodyconcentrationsortitresagainstdiphtheria，tetanus，thethree poliovirustypesandPRPandmorethan89.6%subjectswereseropositiveforanti-FHAand anti-PRN;38.2%ofsubjectswereseropositiveforanti-PT.
- Astrongincreaseinanti-HBconcentrations,ofamagnitudesimilartotheresponsetothe secondyearbooster,wasobservedaftertheHBVvaccinechallenge,indicativeofthepresence of immune memory to HBV.

<div style=\"page-break-after: always\"></div>

- After theHBVvaccinechallenge,98.9%ofthesubjectsprimedwiththeDTPa-HBV-IPV/Hib concentrations≥100mIu/ml.Ananamnesticresponsewasobservedin98.9%ofthe subjects.
- TheHBVvaccinewaswelltolerated,grade3solicitedsymptomswerereportedforlessthan 1%of the subjects and noSAEs were reported.

|       |        | 213mUml   | 213mUml                                      | 100mlUfml   | 100mlUfml                                   | GMC                                                             | GMC    | GMC     |
|-------|--------|-----------|----------------------------------------------|-------------|---------------------------------------------|-----------------------------------------------------------------|--------|---------|
|       |        |           | 95%C                                         | 95%Cl       | 95%Cl                                       |                                                                 | 95%0   | 95%0    |
| Group | Timing |           | 鑫%LLUL                                       | 95%C 7077%  | LLUL                                        | valus                                                           | LL     | UL      |
| Croup | Fre    | 186       | 16588.788392.914578071383.76333927.1         |             | 41.2                                        | 37.3                                                            | 28.9   | 48.2    |
|       | Post   |           |                                              |             | 18718699597190018598.996299.917593.689.1968 | 41335                                                           | 2967.9 | 57571   |
| Grup2 |        |           | 910066.4400777.840.097.222222.8              |             | 60.0                                        | 38.5                                                            | 13.2   | 1117    |
|       | Post   |           | 100664100100864100910086.4100                |             |                                             | 76985                                                           | 13144  | 45089.6 |
|       | Prs.   |           | 19517489284.093.215277.971.58366533326.840.4 |             |                                             | 374                                                             | 29.2   | 47.9    |
|       |        |           |                                              |             |                                             | Post|19619599.5|97.2|40019499:096.4|99.9|184939|89.5|95.84253.3 | 3078.6 | 5876.2  |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## DTPa-HBV-IPV-111

- vaccine in subjects aged 4-6 years, previously primed and boosted with 4 doses of Infanrix hexainthefirsttwoyearsoflife.
- Conclusions(seeTablebelow):At4.6yearsofage,onaverage3.6yearsaftertheDTPaHBV-IPV/Hibboosterdosegiveninthesecondyearoflife,86.4%ofthesubjectsintheATP
- Atthattime,over9o%ofthesubjectsstillhadseroprotectiveantibodyconcentrationsortitres againstdiphtheria,poliovirustypes1,2&amp;3andPRPandwereseropositiveforanti-FHA and anti-PRN;74.7%of thesubjectsstillhadseroprotectiveconcentrationsofanti-tetanus antibodiesand25.4%wereseropositiveforanti-PT.
- Astrongincreaseinanti-HBsconcentrations,ofahighermagnitudethantheresponsetothe secondyearbooster,wasobserved aftertheHBVvaccinechallenge,indicativeofthepresence ofimmunememorytoHBV.
- AftertheHBVvaccinechallenge,98.4%ofthesubjectshadanti-HBantibodyconcentrations≥ 10 mIU/ml and 92.0%had anti-HB antibody concentrations≥ 100mIU/ml.An anamnestic response totheHBVvaccinechallengewasobserved in95.7%ofsubjects.
- TheHBVvaccinechallengedosewaswelltolerated.Grade3solicitedsymptomswerereported foronly1%ofsubjects.NoSAEswerereported.

## Response to fhe hepatitisB challenge dose (ATP immunogenicity cohort):

- Prior to administrationof theHBVvaccime challenge dose,86.0%ofsubjects had seroprotective levelsofanti-HBs antibodies and 53.8%had anti-HBs antibody concentrations≥100 mIU/ml
- A strong response to the HBV challenge,with observation ofa 83-fold increase in anti-HBs GMC. indicative of the presence ofimmune memorywas observed. One month afer the HBVvaccine challenge dose,98.4%of the subjects had anti-HBs antibody concentrations≥10 mIU/ml and 92.0%had anti-HBsantibody concentrations≥100 mIU/ml
- Overall. 95.7% of the subjects mounted an anammestic response to the HBV vaccine challenge.

Synopsis table 2:Percentage of subjects with anti-HBs antibody concentrations ofat least 10 mlU/ml.at least 100 mIU/ml and geometric mean concentrations (GMC) before and one month after the challenge dose (ATP cohort for immunogenicity).

Primary-086=Subjectswhoreceived theirprimaryvaccinationcourse instudy2177441086

<!-- image -->

|                       |               |        |     | ≥3.3mlUml   | ≥3.3mlUml                   | ≥10mlUml   | ≥10mlUml         | ≥100mlU/ml   | ≥100mlU/ml                               | GMC     | GMC    | GMC     |
|-----------------------|---------------|--------|-----|-------------|-----------------------------|------------|------------------|--------------|------------------------------------------|---------|--------|---------|
|                       |               |        |     | 95%CI       | 95%CI                       | 95%CI      | 95%Cl            | %            | %                                        | 95%Cl   | 95%Cl  | 95%Cl   |
| Group                 | Sub Group     | Timing | N   | n           | LL UL                       |            | LLUL             |              | LL UL                                    |         | LL     | UL      |
| Allsubjects           | Allsubjects   | Pre    | 186 | 169         | 90.985.894.616086.080.290.7 |            |                  |              | 10053.846.361.1                          | 95.5    | 71.5   | 127.7   |
|                       |               | Post   | 188 | 186         | 98.996.2 666                | 185        | 98.495.499.7     | 173          | 92.087.295.5                             | 7904.3  | 5611.5 | 11133.9 |
| Primary- 086          | Infanrix      | Pre    | 67  | 66          | 98.592.0 100                | 61         | 91.0|81.596.6    | 42           | 62.750.074.2                             | 180.4   | 113.7  | 286.3   |
| (2.4.6m)              | hexa alone    | Post   | 89  | 68          | 10094.7100                  | 68         |                  |              | 10094.71006494.185.698.41                | 10125.2 | 5908.2 | 17351.9 |
| Primary- 078 (3,4,5m) | Infanrix      | Pre    | 51  | 46          | 90.278.696.74               |            |                  |              | 4588.276.195.63058.844.272.4             | 109.8   | 63.8   | 189.0   |
|                       | hexa alone    |        | 52  | 51          | 98.189.71005                |            | 5096.286.899.549 |              | 994.284.198.8                            | 11255.7 | 5778.6 | 21923.9 |
|                       | Infanix       | Pre    | 68  | 57          |                             |            |                  |              | 83.872.991.65479.467.988.32841.229.453.8 | 46.0    | 28.6   | 73.9    |
|                       | hexa* Prevnar | Post   | 68  | 67          |                             |            |                  |              |                                          | 4709.0  | 2593.1 | 8551.5  |

Primary-078=Subjects who received their primary vaccination course instudy 217744/078

GMC=geometric mean antibody concentration,calculated forall subjects.Antibody concentrafions below the cut-offof3.3 mlUimlwere given an arbitrary value of onehalfthe cut-offorthepurpose ofcalculating the GMC.

PrePriorto the administration of challenge dose,Post One month after the challenge dose

N=numberof subjects with available results;n (%)=number (percentege)of subjects with antibody concentrations above the specified cut-off;95% Cl:LL,UL= exact 95% confidence interval; lower and upper limits

<div style=\"page-break-after: always\"></div>

## DTPa-HBV-IPV-112

- Primaryobjective:Toassesstheanti-HBsantibodyresponsetoachallengedoseofHBV vaccine(Engerix-BKinder)insubjectsat4-5yearsof age,previouslyvaccinatedwithfour dosesofInfanrixhexainthefirsttwoyearsoflife.
- Conclusions(Table2and3):Persistingseroprotectiveanti-HBsantibodyconcentrations Infanrix hexa inroutine clinical practice.
- A strongincrease inanti-HBsGMC(103-fold)wasobservedinresponse totheHBVvaccine challenge.
- OnemonthafteradministrationoftheHBVvaccinechallenge,98.6%of thesubjectshadantiHBsantibodyconcentrations≥10mIU/mland95.8%hadanti-HBsantibodyconcentrations≥ 100mIu/ml.An anamnesticresponsewas observed in96.8%of subjects.
- NoSAEwasreported during the study.

## Response to theHepatitisB challenge (ATPimmunogenicity cohort):

Onemonth after the HBV challenge dose:

- A strong response to the challenge dose was observed with a 103-fold increase in anti-HBs GMC, indicative of the presence of immune memory.
- Seroprotective concentrations of anti-HBs antibodies (anti-HBs antibody concentrations ≥10 mIU/ml) were seen in 98.6% of the subjects.
- More than95%of thevaccinees had anti-HBs antibody conceatrations≥100 mIU/ml.
- Overall, 96.8%of the subjects mounted an anamnestic response to the HBV vaccine challenge

Synopsis fable 2:Percentage of subjects with anti-HBs antibody concentrations ofat least 3.3mIU/ml,at least 10 mIU/ml.at least100 mIU/ml and GMC before and onemonth after the challenge dose(ATP cohont for immunogenicity)

GMC=geometicmean antibodyconcentration caiculated on all subjects

|         |     | ≥3.3mlU/ml   | ≥3.3mlU/ml                     | ≥10mlU/ml   | ≥10mlU/ml   | ≥100mlU/ml   | ≥100mlU/ml   | ≥100mlU/ml   | GMC    | GMC   | GMC           |
|---------|-----|--------------|--------------------------------|-------------|-------------|--------------|--------------|--------------|--------|-------|---------------|
|         |     | %            | %                              | 95%CI       | 95%Cl       | 95%Cl        | 95%Cl        | 95%Cl        | 95%Cl  | 95%Cl | 95%Cl         |
| Timing  |     | n            | LLUL                           | n           | UL          | n            | %            |              | value  | LL    | UL            |
| PRE     | 285 |              | 26492.689.095.424385.380.6     |             | 89.2        | 134          | 47.0         | 41.1 53.0    | 83.7   | 66.8  | 104.9         |
| POST286 |     |              | 28499.397.599.928298.696.599.6 |             |             | 274          | 95.8         | 92.897.8     | 8656.1 |       | 6560.711420.9 |

N=number of subjects with available results

95%C|=95%confidence interval;LL=Lower Limit,UL=UpperLimit

POST= One month after the challenge dose

PRE=Pnor to the administration of challenge dose

Synopsis table 3: Anamnestic response to the HBV challenge (ATP cohort for Immunogenicity)

|                      |     | Anamnesticresponse   | Anamnesticresponse   | Anamnesticresponse   | Anamnesticresponse   |
|----------------------|-----|----------------------|----------------------|----------------------|----------------------|
|                      |     |                      |                      | 10%96                | 10%96                |
| Pre-challenge status | N   | n                    |                      | LL                   | UL                   |
| S-                   | 21  | 17                   | 81.0                 | 58.1                 | 94.6                 |
| +S                   | 264 | 259                  | 98.1                 | 95.6                 | 99.4                 |
| Total                | 285 | 276                  | 96.8                 | 94.1                 | 98.5                 |

Total= subjects either seropositive or seronegative at pre-challenge

Response defined as:

Forinitially seronegativesubjects,antibody concentration≥10 mlU/ml atonemonthpost challenge timepoint Forinitially seropositive subjects: antibody concentration at one monthpost challenge timepoint ≥4 fold theprevaccination antibody concentration

N=number of subjects with bothpre-andpost-vaccination results available n(%)=number(percentage)of responders

95% Cl=exact95%confidence interval: LL=lower limit.UL=upper Imit

<div style=\"page-break-after: always\"></div>

## 4. Rapporteur's Overall Conclusion AND RECOMMENDATION

## 4.1.Overallconclusion

A totalof9studiesevaluatingthecommercialformulationofInfanrixHexaareincludedinthecurrent report. Of these, four studies evaluated safety and immunogenicity of the Infanrix Hexa vaccine in primary immunization studies(116,106, 100 and 109)or booster vaccination studies (120 and 117). Study 120 and 117 are the booster studies of primary studies 116 and 109,respectively.Three studies，110,111 and 112,are antibodypersistence studies.Reactogenicity and immunogenicity data of theprimary and booster studies arenot differentfromthosereported ininitial studies.Results of the antibodypersistence studies show that persisting antibodies werepresent in 4to9 year old wasreportedinpreviousstudies.

## 4.2.Recommendation

No further actionrequired.